Robinson Harriet L, Amara Rama Rao
Emory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30329, USA.
Nat Med. 2005 Apr;11(4 Suppl):S25-32. doi: 10.1038/nm1212.
Vaccination, or the deliberate induction of protective immunity by administering nonpathogenic forms of a microbe or its antigens to induce a memory immune response, is the world's most cost-effective medical procedure for preventing morbidity and mortality caused by infectious disease. Historically, most vaccines have worked by eliciting long-lived plasma cells. These cells produce antibodies that limit disease by neutralizing a toxin or blocking the spread of the infectious agent. For these 'B cell vaccines,' the immunological marker, or correlate, for protection is the titer of protective antibodies. With the discovery of HIV/AIDS, vaccine development has been confronted by an agent that is not easily blocked by antibody. To overcome this, researchers who are developing HIV/AIDS vaccines have turned to the elicitation of cellular immunity, or 'T cell vaccines,' which recognize and kill infected cells.
接种疫苗,即通过接种微生物或其抗原的非致病形式来诱导记忆免疫反应,从而有意诱导保护性免疫,是世界上预防传染病所致发病和死亡最具成本效益的医疗程序。从历史上看,大多数疫苗都是通过诱导长寿浆细胞发挥作用的。这些细胞产生抗体,通过中和毒素或阻止传染因子的传播来限制疾病。对于这些“B细胞疫苗”,保护的免疫标志物或相关指标是保护性抗体的滴度。随着艾滋病病毒/艾滋病的发现,疫苗研发面临着一种不易被抗体阻断的病原体。为了克服这一问题,研发艾滋病病毒/艾滋病疫苗的研究人员转而诱导细胞免疫,即“T细胞疫苗”,其可识别并杀死被感染的细胞。